These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22768591)

  • 1. [Novel combined glucose-lowering drug with DPP-4 inhibitor and pioglitazone].
    Fujita Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():642-6. PubMed ID: 22768591
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.
    Patel CG; Kornhauser D; Vachharajani N; Komoroski B; Brenner E; Handschuh del Corral M; Li L; Boulton DW
    Diabetes Obes Metab; 2011 Jul; 13(7):604-14. PubMed ID: 21332626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linagliptin (Tradjenta)--a new DPP-4 inhibitor for type 2 diabetes.
    Med Lett Drugs Ther; 2011 Jun; 53(1367):49-50. PubMed ID: 21701440
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
    Rosenstock J; Lewin AJ; Norwood P; Somayaji V; Nguyen TT; Teeter JG; Johnson SL; Dai H; Terra SG
    Diabet Med; 2011 Apr; 28(4):464-9. PubMed ID: 21392067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A compounding agent of alogliptin and pioglitazone].
    Ueki K
    Nihon Rinsho; 2011 May; 69(5):877-82. PubMed ID: 21595275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Eur J Pharmacol; 2009 Mar; 605(1-3):170-6. PubMed ID: 19171131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL; Lloyd A; Best JH; DeYoung MB; Samyshkin Y; Gaebler JA
    J Med Econ; 2012; 15(4):654-63. PubMed ID: 22369345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Seufert J
    Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response letter to D. Singh-franco et al.
    Owens DR; Del Prato S; Taskinen MR; Gomis R; Forst T; Woerle HJ
    Diabetes Obes Metab; 2012 Nov; 14(11):1054-5. PubMed ID: 23034010
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sulfonylurea-pioglitazone combination agent].
    Hashiramoto M; Kaku K
    Nihon Rinsho; 2012 May; 70 Suppl 3():633-41. PubMed ID: 22768590
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy.
    Bron M; Ayyagari R; Sharma H; Chen K; Bozas A; Wu E
    Postgrad Med; 2014 May; 126(3):47-55. PubMed ID: 24918791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
    Freeman JS
    J Am Osteopath Assoc; 2010 Sep; 110(9):528-37. PubMed ID: 20876838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Mattei P; Boehringer M; Di Giorgio P; Fischer H; Hennig M; Huwyler J; Koçer B; Kuhn B; Loeffler BM; Macdonald A; Narquizian R; Rauber E; Sebokova E; Sprecher U
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1109-13. PubMed ID: 20031405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Trends Pharmacol Sci; 2012 Jun; 33(6):312-22. PubMed ID: 22475684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
    Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
    Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis.
    Tan A; Cao Y; Xia N; Mo Z; Gao F
    Eur J Intern Med; 2010 Oct; 21(5):398-403. PubMed ID: 20816593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.